Indivior’s supplier map: what investors need to know about manufacturing, distribution and concentration

Indivior generates revenue by developing, manufacturing (through partners), and commercializing buprenorphine‑based prescription medicines for opioid dependence; the company monetizes through product sales, exclusive licensing and supply agreements, and carefully structured buyouts and repurchase programs that support capital returns. The business model is heavily outsourced: third‑party manufacturers and specialty distributors execute the physical production and delivery of Indivior’s core brands, while the company retains regulatory, commercial and product stewardship responsibilities. For a consolidated view of counterparties and supplier risks, visit https://nullexposure.com/.

A compact tour of every supplier relationship disclosed by Indivior

Below are concise, source‑backed summaries of every supplier or related counterparty named in Indivior’s FY2024 disclosures and recent announcements.

Curia — manufacturer of SUBLOCADE

Curia manufactures SUBLOCADE (buprenorphine extended‑release) under an explicit manufacturing agreement, making it a core supplier for one of Indivior’s flagship products (Indivior 2024 Form 10‑K).

RB — contract manufacturer for SUBOXONE and SUBUTEX tablets

Indivior contracts with RB to manufacture SUBOXONE and SUBUTEX tablets, positioning RB as a critical tablet‑form manufacturing partner for the company’s oral product lines (Indivior 2024 Form 10‑K).

Aquestive Therapeutics (AQST) — exclusive license and supplier for SUBOXONE Film

SUBOXONE Film is produced under an exclusive license and supply agreement with Aquestive Therapeutics, making Aquestive the sole film supplier for that delivery format (Indivior 2024 Form 10‑K).

Kindeva Drug Delivery — commercial supply partner for OPVEE

Indivior has contracted Kindeva Drug Delivery (formerly Summit BioSciences) for the commercial supply of OPVEE, embedding Kindeva in the commercial manufacturing chain for that product (Indivior 2024 Form 10‑K).

SpecGx LLC — active pharmaceutical ingredient (nalmefene HCl) supplier for OPVEE

SpecGx supplies nalmefene HCl used in OPVEE manufacturing, representing a component‑level supplier for that product’s formulation (Indivior 2024 Form 10‑K).

Aegis Therapeutics, LLC — excipient supplier (dodecyl maltoside) for OPVEE

Aegis provides dodecyl maltoside, an absorption enhancer used in OPVEE’s manufacture, marking it as a specialty excipient supplier integral to product performance (Indivior 2024 Form 10‑K).

PCI Pharma Services — tertiary packaging and commercial logistics

PCI Pharma Services performs tertiary packaging of Indivior’s commercial product, indicating third‑party reliance for final packaging and distribution readiness (Indivior 2024 Form 10‑K).

C4X Discovery — asset acquisition counterparty (INDV‑2000)

Indivior’s 2023 cash outlay included $21 million for acquisition of INDV‑2000 (an oral orexin‑1 receptor antagonist) from C4X Discovery, indicating a supplier/partner relationship in the form of an asset purchase (Indivior 2024 Form 10‑K).

Alar Pharmaceuticals Inc. — licensing deal for ultra‑long‑acting buprenorphine

Indivior paid $15 million to secure global rights to develop, manufacture and commercialize Alar’s portfolio of buprenorphine‑based ultra‑LAI products, positioning Alar as a source of pipeline assets and future supply interplay (Indivior 2024 Form 10‑K).

Morgan Stanley & Co. International Plc — repurchase execution agent

Indivior entered a non‑discretionary agreement with Morgan Stanley to carry out on‑market purchases of ordinary shares, acting as riskless principal for up to $100 million under a share repurchase program (CityBiz, reporting on Indivior announcement, FY2024/FY2025).

Computershare Investor Services PLC — depository and DI mechanics for UK listing actions

Computershare U.K. is the issuer of the U.K. depositary interests and is cited in the company’s plan to cancel the secondary London listing, providing the mechanism for holders to withdraw DIs and convert holdings back into underlying ordinary shares (Indivior statement reported via PR Newswire, FY2025).

What the supplier footprint reveals about Indivior’s operating model

Indivior runs an outsourced manufacturing and distribution posture: the company relies almost exclusively on third parties to manufacture, package, test and distribute its products. That is a strategic decision that reduces capital investment in plants but raises operational dependency on partner compliance with stringent regulatory standards (Indivior 2024 Form 10‑K).

Concentration and spend profile: Indivior discloses contractual obligations across manufacturing and material supply agreements totaling approximately $210 million (before annual price index adjustments), and it recorded contract termination and related supplier charges in 2024 totaling $53 million. These figures indicate material committed spend and potential switching costs for procurement and cash flow planning (Indivior 2024 Form 10‑K).
Criticality and redundancy: The company flags that the absence of redundant manufacturing capacity could cause supply disruptions that would materially affect revenue. Manufacturers and specialty distributors are therefore mission‑critical counterparties, not discretionary vendors.
Global distribution posture: Indivior uses third‑party logistics vendors and a network of specialty pharmacists and distributors to fulfill orders in the U.S. and worldwide, signaling a global supply chain footprint managed through external providers.
Relationship lifecycle and maturity: The supplier mix is a blend of active long‑term contracts and terminated arrangements — Indivior disclosed termination of certain contract manufacturing agreements tied to the decision to discontinue promotion for a product, underscoring dynamic supplier churn and contractual termination exposure in 2024.

For a detailed supplier risk matrix and to benchmark Indivior’s contractual exposures, check https://nullexposure.com/.

How these signals translate to investor risk and operational priorities

Supply risk is a top‑tier commercial risk because healing of revenue depends on uninterrupted product availability; contract manufacturing partners are therefore strategic.
Contract enforcement and quality compliance require active contract and regulatory oversight; material contract commitments increase leverage for suppliers in negotiations.
Capex vs. outsourcing tradeoff: Indivior’s November 2023 acquisition of an aseptic manufacturing facility indicates a deliberate tilt toward selective insourcing to secure long‑term production capacity for key products (company filings summarized in the 2024 10‑K).

Practical steps for investors and operators

Monitor suppliers that are sole or exclusive producers (e.g., Aquestive for film, Curia and RB for injections and tablets) and assess replacement timelines and qualification hurdles.
Stress‑test balance‑sheet resilience against supplier termination charges and committed purchase obligations (Indivior disclosed roughly $210 million of contractual obligations and $53 million of supplier‑related charges in 2024).
Validate logistics continuity for global markets given reliance on specialty distributors and third‑party logistics providers.

For an actionable supplier risk scorecard tailored to Indivior, visit https://nullexposure.com/ for further analysis and benchmarks.

Final read: what matters to portfolio and procurement teams

Indivior’s model delivers strong margins and recurring revenue from branded opioid‑dependence products, but outsourcing concentrates operational risk with a small set of contract manufacturers, specialty suppliers and distributors. Investors should treat supplier disclosures as a material part of the investment thesis: assess counterparty concentration, contractual duration and termination exposure, and the company’s ability to bring production in‑house where strategic. For ongoing monitoring and supplier due diligence workflows, see https://nullexposure.com/.

INDV supplier relationships